OptiNose Stock Forecast, Price & News

-0.03 (-0.83 %)
(As of 06/21/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume16,919 shs
Average Volume378,984 shs
Market Capitalization$190.68 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

OptiNose logo

About OptiNose

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.61 out of 5 stars

Medical Sector

445th out of 2,101 stocks

Pharmaceutical Preparations Industry

213th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

OptiNose (NASDAQ:OPTN) Frequently Asked Questions

Is OptiNose a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose
or view top-rated stocks.

What stocks does MarketBeat like better than OptiNose?

Wall Street analysts have given OptiNose a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OptiNose wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OptiNose's next earnings date?

OptiNose is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for OptiNose

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) released its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. OptiNose had a negative trailing twelve-month return on equity of 1,275.55% and a negative net margin of 179.55%.
View OptiNose's earnings history

How has OptiNose's stock been impacted by Coronavirus?

OptiNose's stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPTN shares have decreased by 29.1% and is now trading at $3.59.
View which stocks have been most impacted by COVID-19

What guidance has OptiNose issued on next quarter's earnings?

OptiNose updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $80 M-, compared to the consensus revenue estimate of $83.50 million.

What price target have analysts set for OPTN?

3 brokers have issued 12-month target prices for OptiNose's stock. Their forecasts range from $10.00 to $19.00. On average, they expect OptiNose's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 280.7% from the stock's current price.
View analysts' price targets for OptiNose
or view top-rated stocks among Wall Street analysts.

Who are OptiNose's key executives?

OptiNose's management team includes the following people:
  • Mr. Peter K. Miller, CEO & Director (Age 60, Pay $1.02M)
  • Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 56, Pay $743.72k)
  • Mr. Keith Alan Goldan, Chief Financial Officer (Age 50, Pay $603.73k)
  • Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 45, Pay $708.26k)
  • Mr. Jonathan Neely, VP of Investor Relations & Bus. Operations
  • Ms. Karen E. Brophy, VP of HR (Age 58)
  • Mr. John Messina, Sr. VP of Clinical Devel. & Medical Affairs
  • Mr. Victor M. Clavelli, Chief Commercial Officer (Age 48)
  • Ms. Helena Kyttari Djupesland, Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)

Who are some of OptiNose's key competitors?

What other stocks do shareholders of OptiNose own?

When did OptiNose IPO?

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Who are OptiNose's major shareholders?

OptiNose's stock is owned by many different institutional and retail investors. Top institutional shareholders include Paradigm Capital Management Inc. NY (4.70%), BlackRock Inc. (4.62%), Massachusetts Financial Services Co. MA (3.35%), Opaleye Management Inc. (1.56%), Wasatch Advisors Inc. (1.45%) and Geode Capital Management LLC (1.05%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud and Victor M Clavelli.
View institutional ownership trends for OptiNose

Which major investors are selling OptiNose stock?

OPTN stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Morgan Stanley, Millennium Management LLC, Massachusetts Financial Services Co. MA, Goldman Sachs Group Inc., Nuveen Asset Management LLC, JPMorgan Chase & Co., and Cubist Systematic Strategies LLC. Company insiders that have sold OptiNose company stock in the last year include Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud, and Victor M Clavelli.
View insider buying and selling activity for OptiNose
or view top insider-selling stocks.

Which major investors are buying OptiNose stock?

OPTN stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Renaissance Technologies LLC, Snow Capital Management LP, GSA Capital Partners LLP, BlackRock Inc., Assenagon Asset Management S.A., Geode Capital Management LLC, and D. E. Shaw & Co. Inc.. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, Michael F Marino III, and Peter K Miller.
View insider buying and selling activity for OptiNose
or or view top insider-buying stocks.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $3.59.

How much money does OptiNose make?

OptiNose has a market capitalization of $190.68 million and generates $49.12 million in revenue each year. The company earns $-99,790,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis.

How many employees does OptiNose have?

OptiNose employs 204 workers across the globe.

What is OptiNose's official website?

The official website for OptiNose is

Where are OptiNose's headquarters?

OptiNose is headquartered at 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.